HuGE Literature Finder
Records
1
-
6
Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. Thorax 2021 Apr . Visser Sabine, Koolen Stijn, van Donk Nadine, van Walree Nico, van der Leest Cor, Cornelissen Robin, van Schaik Ron, Mathijssen Ron, Aerts Joachim, Stricker Bruno |
Folate/homocysteine metabolism and lung cancer risk among smokers. PloS one 2019 14 (4): e0214462. Stanislawska-Sachadyn Anna, Borzyszkowska Joanna, Krzeminski Michal, Janowicz Alicja, Dziadziuszko Rafal, Jassem Jacek, Rzyman Witold, Limon Janu |
Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. The pharmacogenomics journal 2014 Oct 14 (5): 411-7. Corrigan A, Walker J L, Wickramasinghe S, Hernandez M A, Newhouse S J, Folarin A A, Lewis C M, Sanderson J D, Spicer J, Marinaki A |
Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei medical journal 2013 Jul 54 (4): 854-64. Jung Minkyu, Lee Chul Ho, Park Hyung Soon, Lee Ji Hyun, Kang Young Ae, Kim Se Kyu, Chang Joon, Kim Dae Joon, Rha Sun Young, Kim Joo Hang, Cho Byoung Ch |
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer chemotherapy and pharmacology 2011 Dec 68 (6): 1405-12. Metro Giulio, Chiari R, Mare M, Giannarelli D, Tofanetti F R, Minotti V, Ferraldeschi M, Giuffrida D, Marcomigni L, Bennati C, Fischer M J, Meacci M, Bellavita R, Pistola L, Ludovini V, Crinò |
Genetic variants in one-carbon metabolism-related genes contribute to NSCLC prognosis in a Chinese population. Cancer 2010 Dec 116 (24): 5700-9. Jin Guangfu, Huang Jinlin, Hu Zhibin, Dai Juncheng, Tang Rong, Chen Yijiang, Xu Lin, Huang Xinen, Shu Yongqian, Shen Hongbi |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 31, 2023
- Content source: